Arrowhead Pharmaceuticals vs Travere Therapeutics
ARWR and TVTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARWR and TVTX compare
Arrowhead Pharmaceuticals is the larger company, worth 1.3 times as much as Travere Therapeutics ($6.1B against $4.8B).
Travere Therapeutics grew revenue faster over the last twelve months (77.1% versus 16.8% for Arrowhead Pharmaceuticals).
Travere Therapeutics keeps more of each dollar of sales as profit, with a net margin of −7.4% compared with −47.8% at Arrowhead Pharmaceuticals.
Travere Therapeutics scores higher on the StockData Score (6 against 5 for Arrowhead Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARWR | TVTX |
|---|---|---|
| Size and price | ||
| Market cap | $6.1B | $4.8B |
| Share price | $42.99 | $51.10 |
| Change, 1 year | 4.2% | 48.1% |
| Change, 5 years | −40.3% | 76.0% |
| Beta (5Y) | 1.57 | 1.91 |
| Employees | 711 | 497 |
| StockData Score | ||
| Total score | 5 | 6 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 2 | 2 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 9.1× | 8.1× (better) |
| P/B | 13.0× (better) | 196× |
| EV/EBITDA | – | 197× |
| FCF yield | −1.2% | – |
| Fair value | $31.89 | $6.01 |
| Margin of safety | −34.8% (better) | −751% |
| Growth | ||
| Revenue growth (TTM) | 16.8% | 77.1% (better) |
| Revenue growth, 5Y average | 56.6% (better) | 19.9% |
| Profitability | ||
| Gross margin | – | 98.6% |
| Operating margin | −33.8% | −6.8% (better) |
| Net margin | −47.8% | −7.4% (better) |
| FCF margin | −11.2% | – |
| Return on equity | −64.8% (better) | −152% |
| Financial health | ||
| Interest coverage | −2.4× (better) | −4.3× |
| Current ratio | 5.90 (better) | 4.05 |
| Altman Z-score | 1.69 | 2.29 (better) |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 84.6% | 112% |
| Held by insiders | 4.0% | 1.6% |
| Insider net buying, 12 months | −$36.9M (better) | −$110M |
| Short interest, % of float | 8.5% | 10.3% |
Go deeper
- ARWR stock overview
- ARWR income statement
- ARWR valuation and score
- TVTX stock overview
- TVTX income statement
- TVTX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.